FDA, CDC, and NIH Co-sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
Hiwot Hiruy,Shukal Bala,James M Byrne,Kerian Grande Roche,Seong H Jang,Peter Kim,Sumathi Nambiar,Dan Rubin,Yuliya Yasinskaya,Laura H Bachmann,Kyle Bernstein,Radu Botgros,Sue Cammarata,Ricardo L Chaves,Carolyn D Deal,George L Drusano,Erin M Duffy,Ann E Eakin,Steve Gelone,Thomas Hiltke,Edward W Hook III,Ann E Jerse,Candice J McNeil,Lori Newman,Seamus O'Brien,Caroline Perry,Hilary E L Reno,Raul A Romaguera,Junko Sato,Magnus Unemo,Teodora E C Wi,Kimberly Workowski,Graeme A O'May,Sunita J Shukla,John J Farley
DOI: https://doi.org/10.1093/cid/ciae386
IF: 20.999
2024-07-26
Clinical Infectious Diseases
Abstract:There is an unmet need for developing drugs for the treatment of gonorrhea, due to rapidly evolving resistance of Neisseria gonorrhoeae against antimicrobial drugs used for empiric therapy, an increase in globally reported multidrug resistant cases, and the limited available therapeutic options. Furthermore, few drugs are under development. Development of antimicrobials is hampered by challenges in clinical trial design, limitations of available diagnostics, changes in and varying standards of care, lack of robust animal models, and clinically relevant pharmacodynamic targets. On April 23, 2021, the U.S. Food and Drug Administration; Centers for Disease Control and Prevention; and National Institute of Allergy and Infectious Diseases, National Institutes of Health co-sponsored a workshop with stakeholders from academia, industry, and regulatory agencies to discuss the challenges and strategies, including potential collaborations and incentives, to facilitate the development of drugs for the treatment of gonorrhea. This article provides a summary of the workshop.
immunology,infectious diseases,microbiology